(-)-DHMEQ

(-)-DHMEQ (dehydroxymethylepoxyquinomicin) is a potent, selective, and irreversible small molecule inhibitor of the nuclear factor kappa B (NF-κB) signaling pathway. Originally designed as a derivative of the antibiotic epoxyquinomicin C, (-)-DHMEQ acts by directly and covalently binding to specific cysteine residues of Rel family proteins (including p65, c-Rel, RelB, and p50), thereby preventing their DNA-binding activity and subsequent nuclear translocation. In addition to its primary NF-κB inhibitory activity, (-)-DHMEQ has been shown to activate the Nrf2-ARE antioxidant pathway, providing cytoprotective effects against oxidative stress and nitric oxide-induced cell death. It has been widely investigated in preclinical models for its anti-inflammatory, immunosuppressive, and anticancer properties, showing efficacy in models of rheumatoid arthritis, atopic dermatitis, asthma, graft-versus-host disease, and various solid and hematological malignancies.

Other names

(-)-dehydroxymethylepoxyquinomicin(2S,3S,4S)-DHMEQ(2S,3S,4S)-dehydroxymethylepoxyquinomicindehydroxymethylepoxyquinomicin